Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.
OBJECTIVE
Whether glucagonlike peptide-I-(7-37) (GLP-I-[7-37]), a naturally occurring intestinal peptide, is insulinotropic in nondiabetic and non-insulin-dependent (type II) diabetic subjects.


METHODS
GLP-I-(7-37) or saline placebo was infused (1-5 ng.kg-1.min-1 for 30 min) in 4 nondiabetic and 11 type II diabetic subjects in the fasting and prandial state. Glucose, insulin, and GLP-I-(7-37) levels were measured.


RESULTS
GLP-I-(7-37) infusion resulted in a 3- to 10-fold increase in peak insulin levels and in insulin area under the curve in nondiabetic and diabetic subjects. In diabetic subjects, infusion concurrent with a standard meal eliminated the postprandial glucose excursion for 60 min after the meal. Insulin-releasing potency of GLP-I-(7-37) was attenuated at decreased glucose levels.


CONCLUSIONS
GLP-I-(7-37) has potent insulinotropic effects in nondiabetic and diabetic subjects. Whether GLP-I-(7-37) is useful as a therapeutic medication in type II diabetes requires further investigation.
Nathan
D M
DM
Diabetes Unit, Massachusetts General Hospital, Boston 02114.
Schreiber
E
E
Fogel
H
H
Mojsov
S
S
Habener
J F
JF
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004435:Eating; D005215:Fasting; D005260:Female; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D006801:Humans; D007328:Insulin / Q000097:blood*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments; D010455:Peptides / Q000494:pharmacology*; D012016:Reference Values; D013997:Time Factors
D001786:Blood Glucose; D007328:Insulin; D010446:Peptide Fragments; D010455:Peptides; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; C051322:glucagon-like peptide 1 (7-37)